Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23547485 | 0.94 | ALDH1A1 (0.52) | CDK9CDK4CDK7ALDH1A1NPC1 | |
| SCHEMBL23547346 | 0.92 | CDK9 (0.51) | CDK9CDK4CDK7ALDH1A1NPC1 | |
| SCHEMBL23547379 | 0.90 | CDK9 (0.49) | CDK9CDK4CDK7ALDH1A1NPC1 | |
| SCHEMBL23547459 | 0.90 | CDK9 (0.49) | CDK9CDK4CDK7ALDH1A1NPC1 | |
| SCHEMBL20971691 | 0.86 | CDK4 (0.71) | CDK9CDK4CDK7ALDH1A1NPC1 | |
| SCHEMBL20971697 | 0.86 | CDK4 (0.71) | CDK9CDK4CDK7ALDH1A1NPC1 | |
| SCHEMBL20971698 | 0.86 | CDK4 (0.71) | CDK9CDK4CDK7ALDH1A1NPC1 | |
| SCHEMBL23547349 | 0.86 | CDK9 (0.54) | CDK9CDK4CDK7CDK2 | |
| SCHEMBL23547361 | 0.86 | CDK9 (0.54) | CDK9CDK4CDK7CDK2 | |
| SCHEMBL23547336 | 0.85 | CDK9 (0.52) | CDK9CDK4CDK7ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113004285-B | Heterocyclic compound, pharmaceutical composition, preparation method, intermediate and application thereof | 苏州信诺维医药科技股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230115907-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF | EVOPOINT BIOSICENCES CO., LTD. (CN) | 2023-04-13 | — | — | US | disclosed |
| EP-4079733-A1 | HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND APPLICATION THEREOF | Evopoint Biosciences Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021121390-A1 | HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND APPLICATION THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| WO-2021121390-A1 | HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND APPLICATION THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| CN-113004285-A | Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and application thereof | 苏州信诺维医药科技股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115907-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF | CDK7, CDK17, CDK8 | CDK9 4/4885CDK4 5/4885CDK7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.